Barinthus Biotherapeutics (BRNS) Current Deferred Revenue (2020 - 2026)
Barinthus Biotherapeutics (BRNS) reported Current Deferred Revenue of $318000.0 for Q1 2026, down 78.23% on a YoY basis from $1.5 million in Q1 2025, and down 77.22% quarter-over-quarter from $1.4 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics has reported Current Deferred Revenue for 6 years, with the latest figure at $318000.0 in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue fell 78.23% year-over-year to $318000.0; the trailing twelve-month figure through Mar 2026 stood at $318000.0 (down 78.23% YoY), and the FY2025 full-year result was $1.4 million, down 19.68% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $318000.0, down from $1.4 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $2.0 million in Q3 2024, with the low at $111000.0 in Q3 2022.
- Historically, Current Deferred Revenue has averaged $1.0 million across 4 years, with a median of $1.4 million in 2025.
- Annual changes were most pronounced in 2025 — Current Deferred Revenue soared 81.76% — and 2026, when it tumbled 78.23%.
- Barinthus Biotherapeutics' Current Deferred Revenue stood at $111000.0 in 2022, then soared by 1465.77% to $1.7 million in 2024, then decreased by 19.68% to $1.4 million in 2025, then slumped by 77.22% to $318000.0 in 2026.
- The last three Current Deferred Revenue figures came in at $318000.0 (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Barinthus Biotherapeutics | 27.08 Mn | -40.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 318,000.00 |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.53 Mn |
| Mar 31, 2025 | 1.46 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Sep 30, 2024 | 2.04 Mn |
| Jun 30, 2024 | 839,000.00 |
| Mar 31, 2024 | 1.43 Mn |
| Sep 30, 2022 | 111,000.00 |
| Jun 30, 2022 | 136,000.00 |
| Mar 31, 2022 | 162,000.00 |
| Dec 31, 2021 | 182,000.00 |
| Sep 30, 2021 | 196,000.00 |
| Jun 30, 2021 | 217,000.00 |
| Mar 31, 2021 | 346,000.00 |
| Dec 31, 2020 | 245,000.00 |